Market Overview:
The global cancer screening tests market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The market growth is attributed to the increasing incidence of cancer, technological advancements in cancer screening tests, and rising awareness about early detection of cancer. Based on type, the global cancer screening tests market is segmented into physical exam, imaging tests, genetic tests, and other types. The imaging test segment is expected to grow at the highest CAGR during the forecast period owing to technological advancements in this field that have led to introduction of new and advanced diagnostic techniques such as computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and ultrasound. Based on application, the global cancer screening tests market is segmented into hospital-based clinics, laboratory-based clinics, and other applications. The hospital-based clinic segment accounted for the largest share of the global market in 2017 owing to increasing number of hospitals worldwide coupled with rising demand for early diagnosis and treatment of various types of cancers.
Product Definition:
Cancer screening tests are tests that are used to screen for cancer in people who do not have any symptoms. Cancer screening tests can help find cancer early, when it is more likely to be cured.
Physical Exam:
Physical Exams are the most common and traditional method used for cancer screening. They are also known as clinical or laboratory tests. Physical exams include complete body scans, blood tests, bone density testing, CT/ MRI Scans and ultrasound imaging among others.
Imaging Tests:
Imaging tests are the procedures that help in creating images of internal organs using X-rays, ultrasound or CT scans. These tests are used for cancer screening as well as to study other diseases like kidney stones, gallbladder problems and inflammation. The increasing prevalence of cancer is expected to boost the demand for these imaging tests over the forecast period.
Application Insights:
The hospital application segment dominated the global cancer screening tests market in 2017. This can be attributed to factors such as availability of advanced healthcare facilities and highly skilled medical professionals. Moreover, increasing awareness about early detection among patients is also driving the demand for these tests in hospitals across the globe.
Clinic applications are expected to witness a lucrative CAGR of XX% during the forecast period owing to rising awareness about early diagnosis and effective treatment options for various cancers. Furthermore, an increase in spending capacity among consumers is likely to fuel product demand from clinics across various regions during the forecast period.
Physical exams performed by oncologists at outpatient departments (OPD) account for a major share of revenue generated through this segment owing to factors such as high usage rate and wide scope of application at OPDs across different regions worldwide.
Regional Analysis:
North America dominated the global cancer screening tests market in 2017. This can be attributed to the presence of a large number of players in this region, which has resulted in an increased availability and adoption of technologically advanced products. In addition, high healthcare expenditure and government initiatives for early detection & treatment are some other factors contributing to the growth of this regional market. For instance, as per NCI’s Cancer Target Discovery and Development Network (CTDDN), over 40% population aged 50 years or more will be targeted for cancer screening programs through PSA blood test followed by biopsy or imaging test if necessary based on results obtained from PSA blood test alone.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the global cancer screening tests market. According to a study by the World Health Organization (WHO), an estimated 14 million new cases of cancer were diagnosed in 2012, and this number is expected to rise to 24 million by 2030. This rising incidence of cancer is primarily attributed to the aging population and lifestyle changes such as smoking and obesity.
- Growing awareness about early detection: There is a growing awareness among people about the importance of early detection for various diseases, including cancer. This has led to an increase in demand for screening tests, which in turn is driving growth in the globalcancer screening tests market.
- Technological advancements: The development of new and innovative technologies has helped improve accuracy and efficiencyofcancer screeningtests, thereby boosting demandfor thesetests globally. For instance, recent technological advancements have ledtothe development oftests that can detect cancers at very early stages, when they are most treatable .Thisis helping drivegrowthintheglobalcancer screeningsmarket .
Scope Of The Report
Report Attributes
Report Details
Report Title
Cancer Screening Tests Market Research Report
By Type
Physical Exam, Imaging Tests, Genetic Tests, Other
By Application
Hospital, Clinic, Lab, Other
By Companies
Hologic, Siemens, GRAIL, Carestream Health, Philips, Shimadzu, Canon Medical Systems, Hitachi, Esaote, Agilent Technologies, Abbott, Beckman Coulter, QIAGEN, R-Biopharm, Sysmex, Thrive Early Early Detection, Guardant Health
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
197
Number of Tables & Figures
138
Customization Available
Yes, the report can be customized as per your need.
Global Cancer Screening Tests Market Report Segments:
The global Cancer Screening Tests market is segmented on the basis of:
Types
Physical Exam, Imaging Tests, Genetic Tests, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Lab, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Hologic
- Siemens
- GRAIL
- Carestream Health
- Philips
- Shimadzu
- Canon Medical Systems
- Hitachi
- Esaote
- Agilent Technologies
- Abbott
- Beckman Coulter
- QIAGEN
- R-Biopharm
- Sysmex
- Thrive Early Early Detection
- Guardant Health
Highlights of The Cancer Screening Tests Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Physical Exam
- Imaging Tests
- Genetic Tests
- Other
- By Application:
- Hospital
- Clinic
- Lab
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cancer Screening Tests Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cancer screening tests are blood tests that can help identify cancer early. They can also help determine if treatment is needed.
Some of the major players in the cancer screening tests market are Hologic, Siemens, GRAIL, Carestream Health, Philips, Shimadzu, Canon Medical Systems, Hitachi, Esaote, Agilent Technologies, Abbott, Beckman Coulter, QIAGEN, R-Biopharm, Sysmex, Thrive Early Early Detection, Guardant Health.
The cancer screening tests market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cancer Screening Tests Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cancer Screening Tests Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cancer Screening Tests Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cancer Screening Tests Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cancer Screening Tests Market Size & Forecast, 2018-2028
4.5.1 Cancer Screening Tests Market Size and Y-o-Y Growth
4.5.2 Cancer Screening Tests Market Absolute $ Opportunity
Chapter 5 Global Cancer Screening Tests Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Cancer Screening Tests Market Size Forecast by Type
5.2.1 Physical Exam
5.2.2 Imaging Tests
5.2.3 Genetic Tests
5.2.4 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Cancer Screening Tests Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Cancer Screening Tests Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Lab
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cancer Screening Tests Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cancer Screening Tests Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Cancer Screening Tests Analysis and Forecast
9.1 Introduction
9.2 North America Cancer Screening Tests Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Cancer Screening Tests Market Size Forecast by Type
9.6.1 Physical Exam
9.6.2 Imaging Tests
9.6.3 Genetic Tests
9.6.4 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Cancer Screening Tests Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Lab
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Cancer Screening Tests Analysis and Forecast
10.1 Introduction
10.2 Europe Cancer Screening Tests Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Cancer Screening Tests Market Size Forecast by Type
10.6.1 Physical Exam
10.6.2 Imaging Tests
10.6.3 Genetic Tests
10.6.4 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Cancer Screening Tests Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Lab
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Cancer Screening Tests Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Cancer Screening Tests Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Cancer Screening Tests Market Size Forecast by Type
11.6.1 Physical Exam
11.6.2 Imaging Tests
11.6.3 Genetic Tests
11.6.4 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Cancer Screening Tests Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Lab
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Cancer Screening Tests Analysis and Forecast
12.1 Introduction
12.2 Latin America Cancer Screening Tests Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Cancer Screening Tests Market Size Forecast by Type
12.6.1 Physical Exam
12.6.2 Imaging Tests
12.6.3 Genetic Tests
12.6.4 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Cancer Screening Tests Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Lab
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Cancer Screening Tests Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Cancer Screening Tests Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Cancer Screening Tests Market Size Forecast by Type
13.6.1 Physical Exam
13.6.2 Imaging Tests
13.6.3 Genetic Tests
13.6.4 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Cancer Screening Tests Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Lab
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cancer Screening Tests Market: Competitive Dashboard
14.2 Global Cancer Screening Tests Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Hologic
14.3.2 Siemens
14.3.3 GRAIL
14.3.4 Carestream Health
14.3.5 Philips
14.3.6 Shimadzu
14.3.7 Canon Medical Systems
14.3.8 Hitachi
14.3.9 Esaote
14.3.10 Agilent Technologies
14.3.11 Abbott
14.3.12 Beckman Coulter
14.3.13 QIAGEN
14.3.14 R-Biopharm
14.3.15 Sysmex
14.3.16 Thrive Early Early Detection
14.3.17 Guardant Health
